Patents by Inventor Huamao Wang

Huamao Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOLOGIC EFFECTOR CELL OF TARGETED CLD18A2, AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20250230232
    Abstract: Disclosed are a chimeric antigen receptor (CAR) targeting CLD18A2, and preparation method and use thereof. The extracellular binding region of the CAR comprises a protein specifically recognizing CLD18A2. The immune effector cell modified by the CAR can be used to treat tumors such as pancreatic cancer and stomach cancer.
    Type: Application
    Filed: August 15, 2024
    Publication date: July 17, 2025
    Inventors: Huamao Wang, Bo Song, Xiumei Cai
  • METHOD AND COMPOSITION FOR TREATING TUMORS
    Publication number: 20250177544
    Abstract: Provided in the present invention are a composition of immune effector cells and a treatment kit including the composition of immune effector cells, wherein the composition of immune effector cells comprises an initial dose of immune effector cells and a subsequent dose of immune effector cells.
    Type: Application
    Filed: November 26, 2024
    Publication date: June 5, 2025
    Inventors: Zonghai Li, Huamao Wang, Min Zhou
  • METHOD FOR TREATING TUMOR USING IMMUNE CELL
    Publication number: 20250114438
    Abstract: The present application provides a new adjuvant treatment method for treating tumors, reducing tumor recurrence, inhibiting tumor growth, or inducing tumor necrosis, wherein the method comprises the following: after selecting patients with cancer (for example, liver cancer, pancreatic cancer, gastric cancer, or gastroesophageal junction tumor) in need thereof for tumor local treatment, a therapeutically effective amount of immune cells (for example, CAR-T cells) is administered as a new adjuvant treatment.
    Type: Application
    Filed: October 7, 2024
    Publication date: April 10, 2025
    Applicant: CARSGEN THERAPEUTICS CO., LTD.
    Inventors: Zonghai LI, Huiping GAO, Hua JIANG, Huamao WANG
  • Method and composition for treating tumors
    Patent number: 12186343
    Abstract: Provided in the present invention are a composition of immune effector cells and a treatment kit including the composition of immune effector cells, wherein the composition of immune effector cells comprises an initial dose of immune effector cells and a subsequent dose of immune effector cells.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: January 7, 2025
    Assignee: CRAGE MEDICAL CO., LIMITED
    Inventors: Zonghai Li, Huamao Wang, Min Zhou
  • Antibody against glypican-3 and application thereof
    Patent number: 12168061
    Abstract: The present invention provides an antibody against glypican-3 (GPC3) and application thereof, and the antibody comprises a single chain antibody and humanized antibody.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: December 17, 2024
    Assignee: CRAGE MEDICAL CO., LIMITED
    Inventors: Huamao Wang, Bo Song
  • ANTIBODY AGAINST GLYPICAN-3 AND APPLICATION THEREOF
    Publication number: 20240342305
    Abstract: The present invention provides an antibody against glypican-3 (GPC3) and application thereof, and the antibody comprises a single chain antibody and humanized antibody.
    Type: Application
    Filed: May 16, 2024
    Publication date: October 17, 2024
    Inventors: Huamao WANG, Bo SONG
  • Immunologic effector cell of targeted CLD18A2, and preparation method and use thereof
    Patent number: 12098199
    Abstract: Disclosed are a chimeric antigen receptor (CAR) targeting CLD18A2, and preparation method and use thereof. The extracellular binding region of the CAR comprises a protein specifically recognizing CLD18A2. The immune effector cell modified by the CAR can be used to treat tumors such as pancreatic cancer and stomach cancer.
    Type: Grant
    Filed: November 9, 2021
    Date of Patent: September 24, 2024
    Assignee: CRAGE MEDICAL CO., LIMITED
    Inventors: Huamao Wang, Bo Song, Xiumei Cai
  • COMPOSITIONS AND METHODS OF CELLULAR IMMUNOTHERAPY
    Publication number: 20240269175
    Abstract: Disclosed herein are methods of treating a subject exhibiting a solid tumor that expresses Glypican-3 (GPC3). The methods typically utilize g GPC3 chimeric antigen receptor immunoresponsive cells to a subject in need thereof to effect killing of tumor cells.
    Type: Application
    Filed: February 24, 2023
    Publication date: August 15, 2024
    Inventors: Zonghai LI, Huiping GAO, Peng WANG, Hua JIANG, Huamao WANG
  • METHOD FOR TRANSDUCING CELLS WITH VIRAL VECTOR
    Publication number: 20240182920
    Abstract: Provided is a method for transducing cells with a viral vector, and further provided are cells obtained through recombination or heterologous gene transduction and compositions thereof, and a method for using same in adoptive immunotherapy. Under the premise of not affecting the expression of recombinant nucleic acid, the method shortens the activation and transduction time during the preparation process of genetically engineered cells.
    Type: Application
    Filed: January 22, 2021
    Publication date: June 6, 2024
    Inventors: Huamao WANG, Huiping GAO, Xiao TONG, Yefeng YAO, Yinyu ZHU, Zonghai LI
  • LOW-TEMPERATURE STORAGE OF BIOLOGICAL SAMPLES
    Publication number: 20230148586
    Abstract: The present application relates to the field of cell biology. The present application provides a cryopreservation medium for cryogenic storage of a biological sample, particularly a cryopreservation medium for cryogenic storage of cells in an apheresis sample.
    Type: Application
    Filed: April 21, 2021
    Publication date: May 18, 2023
    Applicant: CRAGE MEDICAL CO., LIMITED
    Inventors: Zonghai LI, Huamao WANG, Huiping GAO
  • Compositions and methods of cellular immunotherapy
    Patent number: 11596653
    Abstract: Disclosed herein are methods of treating a subject exhibiting a solid tumor that expresses Glypican-3 (GPC3). The methods typically utilize g GPC3 chimeric antigen receptor immunoresponsive cells to a subject in need thereof to effect killing of tumor cells.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: March 7, 2023
    Assignee: CRAGE MEDICAL CO., LIMITED
    Inventors: Zonghai Li, Huiping Gao, Peng Wang, Hua Jiang, Huamao Wang
  • ANTI-CLAUDIN 18.2 ANTIBODY AND USE THEREOF
    Publication number: 20230061005
    Abstract: Provided is an antibody or antigen binding fragment, capable of recognizing an antigen peptide comprising SEQ ID NO: 7 (KNKKIYDGG); or recognizing an epitope comprising SEQ ID NO: 7 in Claudin 18.2; preferably recognizing a peptide comprising SEQ ID NO: 6 (KNKKIYDGGART); or recognizing an epitope comprising the SEQ ID NO: 6 in the Claudin 18.2.
    Type: Application
    Filed: January 4, 2021
    Publication date: March 2, 2023
    Applicant: CRAGE MEDICAL CO., LIMITED
    Inventors: Zonghai LI, Peng WANG, Zhen LIU, Huamao WANG
  • Antibody targeting IL-13RA2 and use thereof
    Patent number: 11530270
    Abstract: Provided is an antibody that specifically recognizes IL-13RA2, which can be used in the manufacture of a targeting anti-tumor medicament as well as a medicament for diagnosing a tumor.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: December 20, 2022
    Assignee: CRAGE medical Co., Limited
    Inventors: Peng Wang, Huamao Wang
  • BCMA-targeting antibody and use thereof
    Patent number: 11525006
    Abstract: Provided in the present invention are a specific antibody of BCMA and a BCMA-targeting immune effector cell, and also provided are a chimeric antigen receptor-modified T cell prepared using the antibody and the use thereof.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: December 13, 2022
    Assignee: CRAGE medical Co., Limited
    Inventors: Peng Wang, Huamao Wang, Hua Jiang
  • IMMUNOLOGIC EFFECTOR CELL OF TARGETED CLD18A2, AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20220363751
    Abstract: Disclosed are a chimeric antigen receptor (CAR) targeting CLD18A2, and preparation method and use thereof. The extracellular binding region of the CAR comprises a protein specifically recognizing CLD18A2. The immune effector cell modified by the CAR can be used to treat tumors such as pancreatic cancer and stomach cancer.
    Type: Application
    Filed: November 9, 2021
    Publication date: November 17, 2022
    Inventors: Huamao WANG, Bo SONG, Xiumei CAI
  • Polypeptide and antibody bound to polypeptide
    Patent number: 11479603
    Abstract: An antibody for being specifically bound to a pro brain-derived neurotrophic factor (pro-BDNF) and a bound epitope. The antibody and the protein are used for treating autoimmune diseases. By inhibiting the activity induced by the pro-BDNF, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, lupus nephriti, chronic obstructive pulmonary diseases, asthma or cystic fibrosis, multiple sclerosis and other autoimmune diseases are treated.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: October 25, 2022
    Assignee: SHANGHAI YILE BIOTECHNOLOGY CO., LTD.
    Inventors: Xiumei Cai, Ruping Dai, Huamao Wang
  • GPC3 and ASGPR1 double-targeted transgenic immune effector cell and use thereof
    Patent number: 11453860
    Abstract: Provided are a GPC3 and ASGPR1 double-targeted transgenic immune effector cell and use thereof. The cell is an immune effector cell capable of identifying the gene modification of GPC3 and ASGPR1 simultaneously, and the cell can be used in the treatment of GPC3 and ASGPR1 double positive tumours, such as liver cancer.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: September 27, 2022
    Assignee: CRAGE MEDICAL CO., LIMITED
    Inventors: Huamao Wang, Xiumei Cai, Hongxia Zhao, Bo Song, Yuanmei Chen, Yinyu Zhu
  • ANTIBODY FOR ANTI-CLAUDIN 18A2 AND USE THEREOF
    Publication number: 20220185880
    Abstract: Provided in the present invention is an antibody for anti-claudin 18A2 and an immune effector cell targeting claudin 18A2. Also provided are methods for inducing cell death and treating tumours.
    Type: Application
    Filed: August 5, 2021
    Publication date: June 16, 2022
    Inventors: Peng WANG, Hua JIANG, Linlin YANG, Zhimin SHI, Huamao WANG, Zonghai LI
  • IMMUNE EFFECTOR CELL AND USE THEREOF
    Publication number: 20220127570
    Abstract: A geneticall engineered cell. The cell expresses an exogenous receptor binding to an antigen, and expresses increased RUNX3 or exogenous RUNX3. Also provided are a use of the cell and a method for treating tumors.
    Type: Application
    Filed: April 30, 2019
    Publication date: April 28, 2022
    Inventors: Hua JIANG, Huamao WANG, Zonghai LI
  • METHOD AND COMPOSITION FOR TREATING TUMORS
    Publication number: 20220110973
    Abstract: Provided in the present invention are a composition of immune effector cells and a treatment kit including the composition of immune effector cells, wherein the composition of immune effector cells comprises an initial dose of immune effector cells and a subsequent dose of immune effector cells.
    Type: Application
    Filed: March 8, 2019
    Publication date: April 14, 2022
    Inventors: Zonghai LI, Huamao WANG, Min ZHOU